Skip to main content

Table 3 Probability of target attainment of selective levofloxacin dosing regimens for Gram-positive infection with S. pneumoniae a in 5000 virtual patients with 8-h hemodialysis PIRRT at dialysate flow rate of 5 L/h during the initial 72 h

From: In silico trials using Monte Carlo simulation to evaluate ciprofloxacin and levofloxacin dosing in critically ill patients receiving prolonged intermittent renal replacement therapy

Dosing regimens

Early PIRRTb

Late PIRRTc

Day 1 PTA (%)

Day 2 PTA (%)

Day 3 PTA (%)

Mean PTA (%)

Day 1 PTA (%)

Day 2 PTA (%)

Day 3 PTA (%)

Mean PTA (%)

Levofloxacin

500 mg q48h

33.2

0.0

66.0

33

50.0

0.0

76.8

43.5

500 mg q24h

32.4

82.3

93.6

69.4

49.2

87.7

96.3

77.7

750 mg LD, then 250 mg q24h post-PIRRT

90.3

85.5

78.4

84.7

82.4

78.4

73.9

78.3

750 mg LD, then 500 mg q24h post-PIRRT

96.2

98.3

99.0

97.8

83.6

94.6

97.7

91.9

750 mg LD, then 750 mg q24h post-PIRRT

98.8

99.9

99.9

99.6

84.1

98.8

99.9

94.3

  1. Bolded dosing regimens are the ones that attained PTA of ~90 % or greater in both early and late PIRRT, using the smallest daily dose
  2. LD loading dose
  3. aPharmacodynamic target used for Gram-positive infection was AUC24h:MIC ≥50 with MIC = 2 mg/L for levofloxacin (susceptibility breakpoint for Streptococcus pneumoniae)
  4. bEarly PIRRT: when the first fluoroquinolone dose is administered with the commencement of a daily PIRRT session
  5. cLate PIRRT: when the first fluoroquinolone dose is administered 16 h before a daily PIRRT session
Back to article page

Renal Replacement Therapy

ISSN: 2059-1381

Contact us